LH

Laboratory
D

LH

Arincen56/100B

Laboratory executives and insider trading

Adam H. Schechter sold 30,295 shares for 8.44M USD in 5 sales over the last twelve months, the last on 11 August 2026, and bought none on the open market.

Over the last twelve months Laboratory's insiders sold 43,563 shares for 12.42M USD in 22 sales on the open market, and bought 0 shares in 0 purchases.

Insiders over the last twelve months

Insider sales
22
Shares sold
43,563
Value sold
12.42M USD
Insider purchases
0

Insiders buying against selling

Bought on the market
Sold on the market
0
1 week
108.23K USD
0
1 month
497.63K USD
0
3 months
2.95M USD
0
6 months
5.47M USD
0
1 year
12.42M USD
0
2 years
25.73M USD
Sold, decided at the timeSold under a Rule 10b5-1 plan set in advance

Open-market purchases and sales reported on Form 4, by value. Awards, option exercises and shares withheld for tax are not counted. Whether a sale was under a Rule 10b5-1 plan is read from each Form 4 at the SEC (the box exists on filings since April 2023).

Executives and directors

The people who run the company and the directors who reported trades, with what each bought and sold on the open market over the last twelve months. The CEO first, then whoever traded most.

NamePositionAgeShares sold (12 months)Value sold (12 months)Shares bought (12 months)Last saleShares held after
Adam H. Schechter CEOPresident, Chief Executive Officer & Chairman6130,2958.44M USD—11 Aug 2026102,565
Peter J. Wilkinson Senior Vice President & Chief Accounting Officer553,7191.06M USD—3 Aug 20263,108
Kerrii B Anderson Director—3,000954.06K USD—17 Aug 20266,563
Brian J. Caveney Exec VP, President of Biopharma Laboratory Services & Chief Medical and Scientific Officer521,500429.46K USD—24 Feb 202639,411
Richelle P Parham Director—1,078389.40K USD—30 Oct 20262,288
Jonathan C. Meltzer Executive VP & COO—1,105298.76K USD—27 Mar 20263,620
Amy Summy Executive VP, Chief Marketing Officer & Consumer Health Lead60924283.43K USD—4 Aug 20266,956
Kathryn Wright Kyle Executive Vice President, Chief Legal Officer & Corporate Secretary55854227.41K USD—2 Jul 20263,904
Bryan T Vaughn EVP and President, Diagnostics—540175.20K USD—3 Nov 20266,845
Der Vaart Sandra D Van EVP, Corporate Affairs—548156.00K USD—27 Feb 20268,961

Insider sales and purchases by quarter

How many insider sales and purchases were reported each quarter.

Insider sales Insider purchases

Every insider transaction

Insiders must report every trade in the company's shares to the SEC within two business days, on Form 4. Only purchases and sales are trades on the open market; awards, option exercises, shares withheld for tax and gifts come with pay, and the twelve-month totals leave them out.

DateNameTransactionSharesPriceValueShares held afterFiling
3 Nov 2026Bryan T VaughnSale306353.70108.23K USD6,845Form 4
30 Oct 2026Richelle P ParhamSale1,078361.22389.40K USD2,288Form 4
17 Aug 2026Kerrii B AndersonSale3,000318.02954.06K USD6,563Form 4
11 Aug 2026Adam H. SchechterSale4,669320.371.50M USD102,565Form 4
4 Aug 2026Amy SummySale924306.74283.43K USD6,956Form 4
3 Aug 2026Peter J. WilkinsonSale82309.2225.36K USD1,770Form 4
3 Aug 2026Peter J. WilkinsonSale1,338309.23413.75K USD1,770Form 4
2 Jul 2026Kathryn Wright KyleSale92286.1926.33K USD3,904Form 4
2 Jul 2026Bryan T VaughnSale234286.1966.97K USD6,746Form 4
8 Jun 2026Kathryn Wright KyleSale762263.89201.08K USD3,813Form 4
11 May 2026Adam H. SchechterSale5,903254.501.50M USD107,234Form 4
27 Mar 2026Peter J. WilkinsonSale1,633267.05436.09K USD1,852Form 4
27 Mar 2026Jonathan C. MeltzerSale839267.05224.05K USD3,620Form 4
3 Mar 2026Adam H. SchechterSale8,705279.962.44M USD80,773Form 4
27 Feb 2026Der Vaart Sandra D VanSale548284.91156.00K USD2,579Form 4

Common questions about Laboratory's executives and insiders

Source: Financial Modeling Prep

Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Never invest money you cannot afford to lose, and carefully assess the suitability of complex products such as CFDs and derivatives in light of your financial situation. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.

Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

© 2026 - Arincen L.L.C-FZ - License No. 2420098.01. All Rights Reserved.